Opus Genetics, Inc.

Opus Genetics, Inc. (the Company, Opus, we, us, or our ) is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases ( IRDs ), and other types of therapies for additional ophthalmic disorders. Opus was founded in February 2018 as Ocuphire Pharma, Inc. and has since undergone the following transactions: In April 2018, Ocuphire Pharma, Inc. merged with Ocularis Pharma, LLC, the original innovator of phentolamine mesylate ophthalmic solution. In January 2020, Ocuphire Pharma, Inc. obtained from Apexian Pharmaceuticals, Inc. certain rights to its Ref-1 inhibitor program, including APX3330. In November 2020, Ocuphire Pharma, Inc. completed a reverse merger into Rexahn Pharmaceuticals, Inc. ( Rexahn ), a publicly traded company that had ceased its business of drug development activities, and simultaneously raised just over $21 million through an offering of common shares and warrants to purchase common shares. The combined company continued to operate under the name of Ocuphire Pharma, Inc. 5 Table of Contents Opus Genetics, Inc. Form 10-K On October 22, 2024, Ocuphire Pharma, Inc. acquired a private corporation then operating under the name of Opus Genetics Inc. ( Private Opus ) pursuant to the terms of an Agreement and Plan of Merger, dated as of October 22, 2024 (such agreement, the Merger Agreement and the transaction consummated via the Merger Agreement, the Opus Acquisition ), by and among the Company, Opus, and certain merger subsidiaries party thereto.